This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

A Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma

This study is currently recruiting participants.
See Contacts and Locations
Verified June 2017 by Astellas Pharma Inc ( Agensys, Inc. )
Sponsor:
Information provided by (Responsible Party):
Astellas Pharma Inc ( Agensys, Inc. )
ClinicalTrials.gov Identifier:
NCT02639182
First received: December 21, 2015
Last updated: June 6, 2017
Last verified: June 2017
  Purpose
The purpose of this study is to evaluate the progression free survival (PFS), based on investigator radiologic review, of AGS-16C3F compared to axitinib in subjects with metastatic renal cell carcinoma.

Condition Intervention Phase
Metastatic Renal Cell Carcinoma Drug: AGS-16C3F Drug: Axitinib Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Multi-Center, Open Label, Randomized Phase 2 Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma

Resource links provided by NLM:


Further study details as provided by Astellas Pharma Inc ( Agensys, Inc. ):

Primary Outcome Measures:
  • Progression free survival (PFS) [ Time Frame: 24 months ]
    Defined as the time from the date of randomization to the earliest of documented disease progression as defined by Response Evaluation Criteria in Solid Tumors (RECIST) v.1.1 or death from any cause.


Secondary Outcome Measures:
  • PFS calculated based on blinded central radiology assessment per RECIST v.1.1 [ Time Frame: 24 months ]
  • Objective response rate (ORR) based on the investigator's radiographic assessment [ Time Frame: 24 months ]
    ORR is defined as the proportion of subjects who have a best overall response of Complete Response (CR) or Partial Response (PR)

  • Duration of response (DOR) based on the investigator's radiographic assessment [ Time Frame: 24 months ]
    DOR is defined as the time from the date of the first response of CR/PR (whichever is first recorded) to the first date of documented progressive disease or death due to any cause.

  • Overall survival (OS) [ Time Frame: 24 months ]
    OS is defined as the number of months from the date of randomization until the date of death from any cause.

  • Disease control rate (DCR) assessed by the investigator's radiographic assessment [ Time Frame: 24 months ]
    DCR is defined as the proportion of subjets who have a best overall response of Complete Response (CR), Partial Response (PR), or Stable Disease (SD) with a minimum duration of 6 months.

  • Safety profile assessed by Incidence of adverse events (AEs), laboratory tests, vital signs and electrocardiograms (ECG) [ Time Frame: 24 months ]
    Laboratory tests include hematology and chemistry. Vital signs include blood pressure, heart rate, and respiratory rate.


Estimated Enrollment: 134
Actual Study Start Date: May 24, 2016
Estimated Study Completion Date: June 30, 2018
Estimated Primary Completion Date: January 31, 2018 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: AGS-16C3F
AGS-16C3F will be administered as a single 60-minute intravenous (IV) infusion once every 3 weeks.
Drug: AGS-16C3F
Intravenous (IV) infusion
Active Comparator: Axitinib
Axitinib will be administered twice daily continuously, by mouth.
Drug: Axitinib
Oral
Other Name: Inlyta®

  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Histologically confirmed diagnosis of metastatic RCC

    • Non-clear subjects must be ENPP3 positive, defined as IHC H-score ≥15
  • Has evidence of progression on or after the last regimen received:

    • Clear cell subject: must have received at least 2 prior systemic regimens, one of which is an anti-VEGF agent.
    • Non-clear cell subject: must have received at least one prior anti-VEGF regimen
  • Has measurable disease according to Response Criteria for Solid Tumors (RECIST v.1.1)
  • Has Eastern Cooperative Group (ECOG) performance status of 0 or 1
  • Has archive tumor tissue from primary tumor or metastatic site (excluding bone), for which the source and availability have been confirmed.

    • If no archive tissue is available, a biopsy may be performed to obtain tissue.
  • Has adequate organ function including:

    • Hematopoietic function as follows:

      1. Absolute neutrophil count (ANC) ≥ 1.5 x 10 9/L
      2. Platelet count ≥ 100 x 10 9/L
      3. Hemoglobin ≥ 9 g/dL (transfusions are allowed)
    • Renal Function as follows:

      1. Creatinine ≤ 1.5 x upper limit of normal (ULN), or calculated glomerular filtration rate (GFR) > 40 mL/min (Cockcroft-Gault) if creatinine > 1.5x ULN

    • Hepatic function, as follows:

      1. Aspartate aminotransferase (AST) and Alanine aminotransferase (ALT) ≤ 2.5 x ULN or ≤ 5x ULN if known liver metastases
      2. Total bilirubin ≤ 1.5 x ULN
  • Prothrombin time (PT) and activated partial thromboplastin time (aPTT) levels ≤1.5 x ULN

    • If subject is receiving Coumadin (warfarin), a stable international normalization ratio (INR) of 2-3 is required.
  • No clinical symptoms of hypothyroidism
  • Urine Protein to Creatinine Ratio (uPCR) < 2.0

    • If uPCR ≥ 2.0 then a 24-hour urine collection can be performed to qualify. This result must be < 2 g per 24 hours.
  • Female subject must either:

    • Be of non-childbearing potential:

      1. post-menopausal (defined as at least 1 year without any menses) prior to Screening, or
      2. documented surgically sterile
    • Or, if of childbearing potential,

      1. Agree not to try to become pregnant during the study and for 28 days after the final study drug administration
      2. And have a negative serum pregnancy test ≤ 10 days of cycle 1, day 1 (C1D1)
    • And, if heterosexually active, agree to consistently use 2 forms of highly effective birth control* (at least one of which must be a barrier method) starting at Screening and throughout the study period and for 28 days after the final study drug administration.
  • Female subject must agree not to breastfeed starting at Screening and throughout the study period, and for 28 days after the final study drug administration.
  • Female subject must not donate ova starting at Screening and throughout the study period, and for 28 days after the final study drug administration.
  • Male subject and their female spouse/partners who are of childbearing potential must be using highly effective contraception* consisting of 2 forms of birth control (at least one of which must be a barrier method) starting at Screening and continue throughout the study period, and for 90 days after the final study drug administration
  • Male subject must not donate sperm starting at Screening and throughout the study period and, for 90 days after the final study drug administration

Note: *Highly effective forms of birth control include:

  • Consistent and correct usage of established oral contraception.
  • Established intrauterine device (IUD) or intrauterine system (IUS).
  • Barrier methods of contraception: condom or occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository

Exclusion Criteria:

  • Has previously been treated with axitinib, AGS-16C3F, or AGS-16M8F
  • Has untreated brain metastasis. In the case of a solitary brain metastasis which has been resected, there must be evidence of a disease-free interval of at least 3 months post-surgery. For brain metastases treated with whole brain or stereotactic radiation therapy, brain imaging must be stable > 3 months. All subjects previously treated for brain metastases must be stable off corticosteroid therapy for at least 28 days prior to C1D1.
  • Has uncontrolled hypertension defined as blood pressure > 150/90 on medication(s) by 2 blood pressure readings taken at least 1 hour apart.
  • Has gastrointestinal abnormalities including:

    • inability to take oral medication;
    • requirement for intravenous alimentation;
    • prior surgical procedures affecting absorption including total gastric resection;
    • active gastrointestinal bleeding, unrelated to cancer, as evidenced by hematemesis, hematochezia or melena in the past 3 months without evidence of resolution documented by endoscopy or colonoscopy;
    • malabsorption syndromes such as celiac disease, cystic fibrosis, inflammatory bowel disease, systemic sclerosis, and carcinoid syndrome
  • Has ocular conditions such as:

    • Active infection or corneal ulcer
    • Monocularity
    • Visual acuity of 20/70 or worse in both eyes
    • History of corneal transplantation
    • Contact lens dependent (if using contact lens, must be able to switch to glasses during the entire study duration)
    • Uncontrolled glaucoma (topical medications allowed)
    • Uncontrolled or active ocular problems (e.g., retinopathy, macular edema, active uveitis, wet macular degeneration) requiring surgery, laser treatment, or intravitreal injections
    • Papilledema or other active optic nerve disorder
  • Has used any investigational drug (including marketed drugs not approved for this indication) ≤ 14 days of C1D1. No time limit applies to the use of marketed drugs approved for this indication provided that the subject has progressed on the treatment and all toxicities attributable to the drug have resolved, returned to baseline or stabilized.
  • Has known sensitivity to any of the ingredients of:

    • investigational product AGS-16C3F and/or,
    • Inlyta® (axitinib) and/or,
    • 1% prednisolone acetate ophthalmic suspension and any other corticosteroids.
  • Is currently using (i.e., within 14-days prior to first dose) drugs that are known strong CYP3A4/5 inhibitors / inducers.
  • Thromboembolic event (e.g., deep vein thrombosis [DVT] and pulmonary embolism [PE]) ≤ 4 weeks of C1D1.

    • Subjects who had a thromboembolic event ≤ 4 weeks of C1D1 must be receiving adequate anticoagulation treatment for at least 2 weeks before C1D1 and must continue as clinically indicated post first dose
  • Has history bleeding disorders (e.g., pulmonary hemorrhage, significant hemoptysis, menometrorrhagia not responding to hormonal treatment) ≤ 2 months before C1D1
  • Has active angina or Class III or IV Congestive Heart Failure (New York Heart Association CHF Functional Classification System) or clinically significant cardiac disease within 6 months of randomization, including myocardial infarction, unstable angina, Grade 2 or greater peripheral vascular disease, congestive heart failure, or arrhythmias not controlled by medication.
  • Had major surgery ≤ 4 weeks of C1D1
  • Is pregnant (confirmed by positive serum pregnancy test) or lactating
  • Has active infection requiring treatment with systemic (intravenous or oral) anti-infectives (antibiotic, antifungal, or antiviral agent) ≤ 10 days of C1D1
  • Is unwilling or unable to comply with study requirements
  • Has any medical or psychiatric disorder that compromises the ability of the subject to give written informed consent, and/or comply with the study procedures.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02639182

Contacts
Contact: Agensys Clinical Research and Development 424-280-5000 Astellas.registration@astellas.com

  Show 31 Study Locations
Sponsors and Collaborators
Agensys, Inc.
Investigators
Study Director: Medical Director Agensys, Inc.
  More Information

Responsible Party: Agensys, Inc.
ClinicalTrials.gov Identifier: NCT02639182     History of Changes
Other Study ID Numbers: AGS-16C3F-15-3
Study First Received: December 21, 2015
Last Updated: June 6, 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Keywords provided by Astellas Pharma Inc ( Agensys, Inc. ):
Axitinib
Metastatic Renal Cell Carcinoma
AGS-16C3F

Additional relevant MeSH terms:
Carcinoma
Carcinoma, Renal Cell
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Adenocarcinoma
Kidney Neoplasms
Urologic Neoplasms
Urogenital Neoplasms
Neoplasms by Site
Kidney Diseases
Urologic Diseases
Axitinib
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on August 18, 2017